Prediction of therapeutic effect of immune checkpoint inhibitors by early PET-CT evaluation in esophageal cancer

Prediction of therapeutic effect of immune checkpoint inhibitors by early PET-CT evaluation in esophageal cancer - Prediction of therapeutic effect of immune checkpoint inhibitors by early PET-CT evaluation in esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000054917

Enrollment

Registered

2024-08-01

Start date

2024-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

PET-CT imaging 8 days after administration of immune checkpoint inhibitors

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced or recurrent esophageal squamous cell carcinoma scheduled to receive immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: 1)Patients with cancer other than esophageal cancer at the time of administration of immune checkpoint inhibitors 2)Patients with a history of cancer within 5 years of starting immune checkpoint inhibitor therapy

Design outcomes

Primary

Measure	Time frame
Association between ICI best treatment effect and changes in FDG accumulation (SUVmax) in regional non-metastatic lymph nodes on PET-CT	—

Secondary

Measure	Time frame
Overall survival (OS), progression-free survival (PFS), treatment success time (TTF), response rate, disease control rate, and adverse events including irAEs after ICI treatment in relation to changes in FDG accumulation in intra- and extra-regional lymph nodes (non-metastatic and metastatic) and in various organs (lung, thyroid, pancreas, adrenal, etc.) where irAEs can occur	—

Countries

Japan

Contacts

Public ContactTomoki Makino

Osaka University Department of Gastroenterological surgery

tmakino@gesurg.med.osaka-u.ac.jp0668793251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026